Hepanova, Inc. is a clinical-stage global pharmaceutical company founded in California, USA, in 2014. Its core mission is to discover, develop, and commercialize innovative therapeutics for chronic liver diseases with high unmet medical needs. The company's product pipeline focuses on addressing conditions such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma (HCC).
Notable affiliated people and investors include leading figures in the pharmaceutical and biotech industries, although specific names are not publicly disclosed. Key achievements include advancing multiple R&D programs through various stages of clinical trials, demonstrating significant potential in treating chronic liver conditions. Hepanova's impact lies in its commitment to providing groundbreaking treatments that could significantly improve patient outcomes in the realm of liver diseases.
